Skip to main content

Advertisement

SpringerLink
Log in

The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease

  • Original Contributions
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Purpose

There is a strong association between metabolic dysfunction–associated steatotic liver disease (MASLD) and obesity which are both important risk factors for cardiovascular diseases (CVDs). The current study aimed to assess the association of MBS with different CVDs in patients with MASLD.

Materials and Methods

The National Inpatient Sample (NIS) database from 2016 to 2020 were analyzed by using ICD-10 codes. A propensity score matching in a 1:1 ratio was done to match the MBS and non-MBS groups.

Results

After weighted analysis, 1,124,155 and 68,215 patients were included in non-MBS and MBS groups, respectively. MBS was associated with significantly lower risk of hospitalization for coronary artery disease (OR 0.633 (0.569–0.703), p value < 0.001), acute myocardial infarction (OR 0.606 (0.523–0.701), p value < 0.001), percutaneous coronary intervention (OR 0.578 (0.489–0.682), p value < 0.001), and thrombolysis (OR 0.765 (0.589–0.993), p value = 0.044) compared to the non-MBS group in patients with MASLD. Furthermore, MBS was associated with 52% reduced risk of hospitalization for hemorrhagic stroke in patients with MASLD (OR 0.481, 95% CI 0.337–0.686, p value < 0.001). However, ischemic stroke was not significant between the two groups (OR 1.108 (0.905–1.356), p value = 0.322). In addition, MBS was associated with 63% and 60% reduced risk of hospitalization for heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in patients with MASLD (OR 0.373, 95% CI 0.300–0.465 and OR 0.405, 95% CI 0.325–0.504, p value < 0.001 for both), respectively.

Conclusion

The current study showed that MBS is significantly associated with a reduced risk of hospitalization for CVD in patients with MASLD.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

The dataset utilized in this study can be accessed through the Healthcare Cost and Utilization Project (HCUP).

References

  1. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.

    Article  CAS  PubMed  Google Scholar 

  2. Mundi MS, Velapati S, Patel J, et al. Evolution of NAFLD and its management. Nutr Clin Pract. 2020;35(1):72–84.

    Article  PubMed  Google Scholar 

  3. Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61.

    Article  PubMed  Google Scholar 

  5. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002–2030. Ann Trop Med Parasitol. 2006;100(5–6):481–99.

    Article  CAS  PubMed  Google Scholar 

  6. Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. JAMA. 2021;325(18):1829–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98–107.

    Article  CAS  PubMed  Google Scholar 

  8. Chen B, Tang WHW, Rodriguez M, et al. NAFLD in cardiovascular diseases: a contributor or comorbidity? Semin Liver Dis. 2022;42(4):465–74.

    Article  PubMed  Google Scholar 

  9. Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–85.

    Article  CAS  PubMed  Google Scholar 

  10. Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment. Diabetes Metab. 2021;47(2):101215.

    Article  CAS  PubMed  Google Scholar 

  11. Chan WK, Chuah KH, Rajaram RB, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32(3):197–213.

    Article  PubMed  PubMed Central  Google Scholar 

  12. van Veldhuisen SL, Gorter TM, van Woerden G, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43(20):1955–69.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280–9.

    Article  PubMed  Google Scholar 

  14. Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD). Endocr Pract. 2022;28(5):528–62.

    Article  PubMed  Google Scholar 

  15. Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;326(20):2031–42.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Elsaid MI, Li Y, Bridges JFP, et al. Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease. JAMA Netw Open. 2022;5(10):e2235003.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Krishnan A, Hadi Y, Alqahtani SA, et al. Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity. JAMA Netw Open. 2023;6(4):e237188.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. JAMA Network Open. 2020;3(4):e201997-e.

    Article  Google Scholar 

  19. Minhas AMK, Bhopalwala HM, Dewaswala N, et al. Association of non-alcoholic fatty liver disease with in-hospital outcomes in primary heart failure hospitalizations with reduced or preserved ejection fraction. Current Problems Cardiol. 2022;48:101199.

    Article  Google Scholar 

  20. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–73.

    Article  CAS  PubMed  Google Scholar 

  21. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.

    Article  CAS  PubMed  Google Scholar 

  22. Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis. 2018;22(1):133–40.

    Article  PubMed  Google Scholar 

  23. Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine. 2018;97(13):e0214.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Elsaid MI, Bridges JF, Li N, et al. Metabolic syndrome severity predicts mortality in nonalcoholic fatty liver disease. Gastro Hep Advances. 2022;1(3):445–56.

    Article  Google Scholar 

  25. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):637–53.

    Article  CAS  PubMed  Google Scholar 

  26. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–10.

    Article  PubMed  Google Scholar 

  27. Lazarus JV, Mark HE, Colombo M, et al. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther. 2022;55(2):234–43.

    Article  PubMed  Google Scholar 

  28. Hannah WN Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20(2):339–50.

    Article  PubMed  Google Scholar 

  29. Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157–66.

    Article  CAS  PubMed  Google Scholar 

  30. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46.

    Article  PubMed  Google Scholar 

  31. Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396–402.

    Article  PubMed  Google Scholar 

  32. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65.

    Article  PubMed  Google Scholar 

  33. Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterol. 2020;159(4):1290-301.e5.

    Article  Google Scholar 

  34. Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–11.

    Article  PubMed  Google Scholar 

  35. Oliveras A, Molina L, Goday A, et al. Effect of bariatric surgery on cardiac structure and function in obese patients: role of the renin-angiotensin system. The Journal of Clinical Hypertension. 2021;23(1):181–92.

    Article  PubMed  Google Scholar 

  36. Villarreal-Calderón JR, Cuéllar RX, Ramos-González MR, et al. Interplay between the adaptive immune system and insulin resistance in weight loss induced by bariatric surgery. Oxid Med Cell Longev. 2019;2019:3940739.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Seyyedi J, Alizadeh S. Effect of surgically induced weight loss on biomarkers of endothelial dysfunction: a systematic review and meta-analysis. Obes Surg. 2020;30(9):3549–60.

    Article  PubMed  Google Scholar 

  38. Esparham A, Shoar S, Kheradmand HR, et al. The impact of bariatric surgery on cardiac structure, and systolic and diastolic function in patients with obesity: a systematic review and meta-analysis. Obes Surg. 2023;33(1):345–61.

    Article  PubMed  Google Scholar 

  39. Esparham A, Roohi S, Ahmadyar S, Dalili A, Nelson P, Khorgami Z. Impact of bariatric surgery on carotid intima-media thickness, flow-mediated dilation, and nitrite-mediated dilation: a systematic review and meta-analysis. Surg Obesity Related Diseases. 2023;19:1188.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Ali Esparham

  2. Department of Clinical Research, Scientific Writing Corp, Houston, TX, USA

    Saeed Shoar

  3. Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Ali Mehri

  4. Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

    Zhamak Khorgami

  5. Department of Surgery, School of Community Medicine, University of Oklahoma, Tulsa, OK, USA

    Zhamak Khorgami

  6. Bariatric and Metabolic Surgery Program, Newark Beth Israel Medical Center, RWJ Barnabas Health, Rutgers NJ Medical School, Newark, NJ, USA

    Venkat R. Modukuru

Authors
  1. Ali Esparham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saeed Shoar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Mehri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhamak Khorgami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Venkat R. Modukuru
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali Esparham.

Ethics declarations

Ethical Approval

The study was conducted in accordance with the principles of the Declaration of Helsinki.

Conflict of Interest

The authors declare no competing interests.

Informed Consent

Informed Consent does not apply.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Key Points

• MBS was associated with significantly lower risk of hospitalization for CAD, AMI, PCI, and thrombolysis compared to the non-MBS group in patients with MASLD.

• MBS was associated with 52% reduced risk of hospitalization for hemorrhagic stroke in patients with MASLD.

• MBS was associated with 63% and 60% reduced risk of hospitalization for heart failure with reduced ejection fraction and heart failure with preserved ejection fraction in patients with MASLD, respectively.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 18 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Esparham, A., Shoar, S., Mehri, A. et al. The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease. OBES SURG (2024). https://doi.org/10.1007/s11695-024-07238-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11695-024-07238-w

Keywords

Search

Navigation